isoproterenol has been researched along with Disease Exacerbation in 33 studies
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As rats develop myocardial infarction (MI) like lesions when injected with large doses of isoproterenol (ISO), this investigation was designed to evaluate the dose-dependent effects of thymoquinone (TQ) on ISO-induced myocardial injury in rats." | 8.02 | Thymoquinone dose-dependently attenuates myocardial injury induced by isoproterenol in rats via integrated modulations of oxidative stress, inflammation, apoptosis, autophagy, and fibrosis. ( Elhadidy, WF; Farag, MM; Khalifa, AA; Rashad, RM, 2021) |
| " We measured in vivo their metabolic parameters, fasting glucose level, area under the curve (AUC) for glucose level time profile, insulin level time profile, insulin sensitivity index, and chromium distribution." | 7.85 | Isoproterenol exacerbates hyperglycemia and modulates chromium distribution in mice fed with a high fat diet. ( Chang, GR; Chen, WK; Hou, PH; Mao, FC, 2017) |
| "These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure." | 7.72 | Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Ogai, A; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H, 2004) |
| "Furosemide shortened the time to left ventricular dysfunction (35." | 7.72 | Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004) |
| "As rats develop myocardial infarction (MI) like lesions when injected with large doses of isoproterenol (ISO), this investigation was designed to evaluate the dose-dependent effects of thymoquinone (TQ) on ISO-induced myocardial injury in rats." | 4.02 | Thymoquinone dose-dependently attenuates myocardial injury induced by isoproterenol in rats via integrated modulations of oxidative stress, inflammation, apoptosis, autophagy, and fibrosis. ( Elhadidy, WF; Farag, MM; Khalifa, AA; Rashad, RM, 2021) |
| " We measured in vivo their metabolic parameters, fasting glucose level, area under the curve (AUC) for glucose level time profile, insulin level time profile, insulin sensitivity index, and chromium distribution." | 3.85 | Isoproterenol exacerbates hyperglycemia and modulates chromium distribution in mice fed with a high fat diet. ( Chang, GR; Chen, WK; Hou, PH; Mao, FC, 2017) |
| "the aim of this study was to determine whether depressive symptoms are related to alterations in the sensitivity of peripheral blood mononuclear cells to β-adrenergic agonists in patients with heart failure (HF) by measuring in vitro chemotaxis (CTX) to isoproterenol at rest and after acute exercise in patients with HF and controls." | 3.76 | Depression as a potential modulator of Beta-adrenergic-associated leukocyte mobilization in heart failure patients. ( Bosch, J; Bosch, JA; Greenberg, B; Hong, S; Mills, PJ; Redwine, LS; Wirtz, PH; Ziegler, MG, 2010) |
| "These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure." | 3.72 | Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Ogai, A; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H, 2004) |
| "Furosemide shortened the time to left ventricular dysfunction (35." | 3.72 | Furosemide and the progression of left ventricular dysfunction in experimental heart failure. ( Haigney, MC; Hanlon, SU; McCurley, JM; Michalski, M; Wedam, EF; Wei, SK, 2004) |
| "Cardiac hypertrophy was induced in mice either by isoproterenol administration or by aortic constriction." | 1.40 | Erbin is a negative modulator of cardiac hypertrophy. ( Borg, JP; Dagan, N; Foo, RS; Gilon, D; Golomb, E; Kay, G; Marchetto, S; Oppenheim, A; Rachmin, I; Razin, E; Smith, Y; Tshori, S, 2014) |
| "Breast cancer is the most frequent malignancy in women." | 1.40 | Differential β₂-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines. ( Bruzzone, A; Copsel, S; Davio, C; Galés, C; Gargiulo, L; Lüthy, IA; Rivero, EM; Sénard, JM, 2014) |
| "Current research in left ventricular hypertrophy (LVH) has largely focused on its progression and therapeutic mechanisms to prevent or slow its development." | 1.35 | Proteasome inhibition promotes regression of left ventricular hypertrophy. ( Baldwin, AS; Moss, NC; Selzman, CH; Stansfield, WE; Tang, RH; Willis, MS, 2008) |
| "Approximately 40% of patients with type 2 diabetes present with concurrent hypertension at the time of diabetes diagnosis." | 1.35 | Decreased NO signaling leads to enhanced vasoconstrictor responsiveness in skeletal muscle arterioles of the ZDF rat prior to overt diabetes and hypertension. ( Behnke, BJ; Delp, MD; Donato, AJ; Laughlin, MH; Lesniewski, LA; Ray, CA; Woodman, CR, 2008) |
| "To determine whether primary sclerosing cholangitis (PSC) in childhood is associated with abnormalities in cystic fibrosis transmembrane conductance regulator (CFTR)." | 1.34 | Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. ( DaSilva, DA; Freedman, SD; Huang, Q; Jonas, MM; Pall, H; Potvin, KM; Yuan, XW; Zielenski, J, 2007) |
| "When glycosuria is high (20 to 500 mg/dL), there is a selective reduction in the response to alpha1 and beta2 agonists but not to dopamine or serotonin." | 1.32 | Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression. ( Brancaleone, V; Bucci, M; Cicala, C; Cirino, G; Di Lorenzo, A; Farneti, S; Fiorucci, S; Lin, MI; Pinto, A; Roviezzo, F; Sessa, WC, 2004) |
| "To test the hypothesis that dilated cardiomyopathy (DCM) is part of the pathological spectrum of HCM, we studied chamber morphology, exercise tolerance, hemodynamics, isolated heart function, adrenergic sensitivity, and embryonic gene expression in 8- to 11-mo-old male transgenic animals." | 1.31 | Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene. ( Colon-Rivera, C; Freeman, K; Grupp, IL; Iaccarino, G; Koch, WJ; Leinwand, LA; Moore, RL; Olsson, MC; Vikstrom, KL; Weinberger, HD, 2001) |
| "Two signatures of heart failure are activation of the sympathetic nervous system and catecholamine desensitization." | 1.30 | Effects of cardiac denervation on development of heart failure and catecholamine desensitization. ( Asai, K; Ghaleh-Marzban, B; Kudej, RK; Mirsky, I; Patrick, TA; Sato, N; Shannon, RP; Shen, YT; Uechi, M; Vatner, DE; Vatner, SF, 1997) |
| "In a few patients, hypertrophic cardiomyopathy has been reported to progress to a phase characterized by systolic dysfunction and left ventricular dilation, resembling dilated cardiomyopathy." | 1.29 | Response to isoproterenol as a prognostic indicator of evolution from hypertrophic cardiomyopathy to a phase resembling dilated cardiomyopathy. ( Fujieda, K; Iida, K; Iwasaki, Y; Kawano, S; Magdi, ES; Sugishita, Y; Tabei, F; Yamaguchi, I; Yukisada, K, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (21.21) | 18.2507 |
| 2000's | 11 (33.33) | 29.6817 |
| 2010's | 12 (36.36) | 24.3611 |
| 2020's | 3 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, M | 1 |
| Wang, Q | 1 |
| Sun, X | 1 |
| Yin, Q | 1 |
| Chen, J | 1 |
| Xu, L | 1 |
| Xu, C | 2 |
| Peter, AK | 1 |
| Walker, CJ | 1 |
| Ceccato, T | 1 |
| Trexler, CL | 1 |
| Ozeroff, CD | 1 |
| Lugo, KR | 1 |
| Perry, AR | 1 |
| Anseth, KS | 1 |
| Leinwand, LA | 2 |
| Farag, MM | 1 |
| Khalifa, AA | 1 |
| Elhadidy, WF | 1 |
| Rashad, RM | 1 |
| Chang, GR | 1 |
| Chen, WK | 1 |
| Hou, PH | 1 |
| Mao, FC | 1 |
| Xu, Y | 1 |
| Wu, L | 1 |
| Chen, A | 1 |
| Feng, Q | 1 |
| Zhou, L | 1 |
| Miao, K | 1 |
| Yin, B | 1 |
| Li, H | 1 |
| Fan, J | 1 |
| Zhu, Y | 1 |
| Ba, H | 1 |
| Zhang, Z | 1 |
| Chen, F | 1 |
| Wang, J | 1 |
| Zhao, C | 1 |
| Li, Z | 2 |
| Wang, DW | 2 |
| Katsuumi, G | 1 |
| Shimizu, I | 1 |
| Yoshida, Y | 1 |
| Hayashi, Y | 1 |
| Ikegami, R | 1 |
| Suda, M | 1 |
| Wakasugi, T | 1 |
| Nakao, M | 1 |
| Minamino, T | 2 |
| Chachi, L | 1 |
| Alzahrani, A | 1 |
| Koziol-White, C | 1 |
| Biddle, M | 1 |
| Bagadood, R | 1 |
| Panettieri, RA | 1 |
| Bradding, P | 1 |
| Amrani, Y | 1 |
| Rachmin, I | 1 |
| Tshori, S | 1 |
| Smith, Y | 1 |
| Oppenheim, A | 1 |
| Marchetto, S | 1 |
| Kay, G | 1 |
| Foo, RS | 1 |
| Dagan, N | 1 |
| Golomb, E | 1 |
| Gilon, D | 1 |
| Borg, JP | 1 |
| Razin, E | 1 |
| Gargiulo, L | 1 |
| Copsel, S | 1 |
| Rivero, EM | 1 |
| Galés, C | 1 |
| Sénard, JM | 1 |
| Lüthy, IA | 1 |
| Davio, C | 1 |
| Bruzzone, A | 1 |
| Duan, Q | 1 |
| Chen, C | 1 |
| Yang, L | 1 |
| Li, N | 1 |
| Gong, W | 1 |
| Li, S | 1 |
| Soeda, Y | 1 |
| Yoshikawa, M | 1 |
| Almeida, OF | 1 |
| Sumioka, A | 1 |
| Maeda, S | 1 |
| Osada, H | 1 |
| Kondoh, Y | 1 |
| Saito, A | 1 |
| Miyasaka, T | 1 |
| Kimura, T | 1 |
| Suzuki, M | 1 |
| Koyama, H | 1 |
| Yoshiike, Y | 1 |
| Sugimoto, H | 1 |
| Ihara, Y | 1 |
| Takashima, A | 1 |
| Yuan, A | 1 |
| Li, X | 1 |
| Yi, S | 1 |
| Wang, S | 1 |
| Cai, Y | 1 |
| Cao, H | 1 |
| Redwine, LS | 1 |
| Wirtz, PH | 1 |
| Hong, S | 1 |
| Bosch, JA | 1 |
| Bosch, J | 1 |
| Ziegler, MG | 1 |
| Greenberg, B | 1 |
| Mills, PJ | 1 |
| Johnson, CM | 1 |
| Pogwizd, SM | 1 |
| Min, JY | 1 |
| Sullivan, MF | 1 |
| Yan, X | 1 |
| Feng, X | 1 |
| Chu, V | 1 |
| Wang, JF | 1 |
| Amende, I | 1 |
| Morgan, JP | 1 |
| Philipson, KD | 1 |
| Hampton, TG | 1 |
| Borges, JC | 1 |
| Silva, JA | 1 |
| Gomes, MA | 1 |
| Lomez, ES | 1 |
| Leite, KM | 1 |
| Araujo, RC | 1 |
| Bader, M | 1 |
| Pesquero, JB | 1 |
| Pesquero, JL | 1 |
| Badenhorst, D | 1 |
| Veliotes, D | 1 |
| Maseko, M | 1 |
| Tsotetsi, OJ | 1 |
| Brooksbank, R | 1 |
| Naidoo, A | 1 |
| Woodiwiss, AJ | 1 |
| Norton, GR | 1 |
| Bucci, M | 1 |
| Roviezzo, F | 1 |
| Brancaleone, V | 1 |
| Lin, MI | 1 |
| Di Lorenzo, A | 1 |
| Cicala, C | 1 |
| Pinto, A | 1 |
| Sessa, WC | 1 |
| Farneti, S | 1 |
| Fiorucci, S | 1 |
| Cirino, G | 1 |
| Liao, Y | 1 |
| Asakura, M | 1 |
| Takashima, S | 1 |
| Ogai, A | 1 |
| Asano, Y | 1 |
| Shintani, Y | 1 |
| Asanuma, H | 1 |
| Sanada, S | 1 |
| Kim, J | 1 |
| Kitamura, S | 1 |
| Tomoike, H | 1 |
| Hori, M | 1 |
| Kitakaze, M | 1 |
| McCurley, JM | 1 |
| Hanlon, SU | 1 |
| Wei, SK | 1 |
| Wedam, EF | 1 |
| Michalski, M | 1 |
| Haigney, MC | 1 |
| Pall, H | 1 |
| Zielenski, J | 1 |
| Jonas, MM | 1 |
| DaSilva, DA | 1 |
| Potvin, KM | 1 |
| Yuan, XW | 1 |
| Huang, Q | 1 |
| Freedman, SD | 1 |
| Stansfield, WE | 1 |
| Tang, RH | 1 |
| Moss, NC | 1 |
| Baldwin, AS | 1 |
| Willis, MS | 1 |
| Selzman, CH | 1 |
| Lesniewski, LA | 1 |
| Donato, AJ | 1 |
| Behnke, BJ | 1 |
| Woodman, CR | 1 |
| Laughlin, MH | 1 |
| Ray, CA | 1 |
| Delp, MD | 1 |
| Kawano, S | 1 |
| Iida, K | 1 |
| Fujieda, K | 1 |
| Yukisada, K | 1 |
| Magdi, ES | 1 |
| Iwasaki, Y | 1 |
| Tabei, F | 1 |
| Yamaguchi, I | 1 |
| Sugishita, Y | 1 |
| Chen, SA | 1 |
| Chiang, CE | 1 |
| Tai, CT | 1 |
| Lee, SH | 1 |
| Chiou, CW | 1 |
| Ueng, KC | 1 |
| Wen, ZC | 1 |
| Cheng, CC | 1 |
| Chang, MS | 1 |
| Kamp, T | 1 |
| Liebl, B | 1 |
| Haen, E | 1 |
| Emmerich, B | 1 |
| Hallek, M | 1 |
| Sato, N | 1 |
| Vatner, SF | 1 |
| Shen, YT | 1 |
| Kudej, RK | 1 |
| Ghaleh-Marzban, B | 1 |
| Uechi, M | 1 |
| Asai, K | 1 |
| Mirsky, I | 1 |
| Patrick, TA | 1 |
| Shannon, RP | 1 |
| Vatner, DE | 1 |
| Kähönen, M | 1 |
| Tolvanen, JP | 1 |
| Sallinen, K | 1 |
| Wu, X | 1 |
| Pörsti, I | 1 |
| Flammang, D | 1 |
| Erickson, M | 1 |
| McCarville, S | 1 |
| Church, T | 1 |
| Hamani, D | 1 |
| Donal, E | 1 |
| Cox, ME | 1 |
| Deeble, PD | 1 |
| Lakhani, S | 1 |
| Parsons, SJ | 1 |
| Freeman, K | 1 |
| Colon-Rivera, C | 1 |
| Olsson, MC | 1 |
| Moore, RL | 1 |
| Weinberger, HD | 1 |
| Grupp, IL | 1 |
| Vikstrom, KL | 1 |
| Iaccarino, G | 1 |
| Koch, WJ | 1 |
| Ogletree-Hughes, ML | 1 |
| Stull, LB | 1 |
| Sweet, WE | 1 |
| Smedira, NG | 1 |
| McCarthy, PM | 1 |
| Moravec, CS | 1 |
33 other studies available for isoproterenol and Disease Exacerbation
| Article | Year |
|---|---|
β
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Progress | 2020 |
Cardiac Fibroblasts Mediate a Sexually Dimorphic Fibrotic Response to β-Adrenergic Stimulation.
Topics: Adrenergic beta-Agonists; Animals; Disease Models, Animal; Disease Progression; Female; Fibroblasts; | 2021 |
Thymoquinone dose-dependently attenuates myocardial injury induced by isoproterenol in rats via integrated modulations of oxidative stress, inflammation, apoptosis, autophagy, and fibrosis.
Topics: Animals; Antioxidants; Apoptosis; Autophagy; Benzoquinones; Cardiotonic Agents; Disease Progression; | 2021 |
Isoproterenol exacerbates hyperglycemia and modulates chromium distribution in mice fed with a high fat diet.
Topics: Animals; Blood Glucose; Body Weight; Chromium; Creatinine; Diet, High-Fat; Disease Progression; Ener | 2017 |
Protective Effects of Olive Leaf Extract on Acrolein-Exacerbated Myocardial Infarction via an Endoplasmic Reticulum Stress Pathway.
Topics: Acrolein; Animals; Apoptosis; Biological Products; Biomarkers; Cell Line; Cytoprotection; Disease Pr | 2018 |
Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure.
Topics: Aged; Animals; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cytokines; Disease Models, | 2018 |
Catecholamine-Induced Senescence of Endothelial Cells and Bone Marrow Cells Promotes Cardiac Dysfunction in Mice.
Topics: Animals; Bone Marrow Cells; Catecholamines; Cellular Senescence; Disease Progression; Endothelial Ce | 2018 |
Increased β2-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors.
Topics: Albuterol; Asthma; Bronchodilator Agents; Cells, Cultured; Cyclic AMP; Disease Progression; Fibrobla | 2018 |
Erbin is a negative modulator of cardiac hypertrophy.
Topics: Animals; Biomarkers; Cardiomegaly; Carrier Proteins; Disease Progression; Down-Regulation; Extracell | 2014 |
Differential β₂-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines.
Topics: Adrenergic beta-2 Receptor Agonists; Breast Neoplasms; Cell Adhesion; Cell Line; Cell Line, Tumor; C | 2014 |
MicroRNA regulation of unfolded protein response transcription factor XBP1 in the progression of cardiac hypertrophy and heart failure in vivo.
Topics: Animals; Cardiomegaly; Cell Line; Disease Progression; DNA-Binding Proteins; Heart Failure; Humans; | 2015 |
Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups.
Topics: Adrenergic beta-Agonists; Alzheimer Disease; Animals; Behavior, Animal; Blotting, Western; Brain; Ca | 2015 |
The mitogenic effectors of isoproterenol in human hepatocellular carcinoma cells.
Topics: Adrenergic beta-Agonists; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation | 2010 |
Depression as a potential modulator of Beta-adrenergic-associated leukocyte mobilization in heart failure patients.
Topics: Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Chemotaxis; Depression; Disease Progressio | 2010 |
Focal initiation of sustained and nonsustained ventricular tachycardia in a canine model of ischemic cardiomyopathy.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Cardiac Pacing, Artificial; Cardiomyopathies; | 2012 |
Overexpression of Na+/Ca2+ exchanger gene attenuates postinfarction myocardial dysfunction.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Disease Models, Animal; Disease Progression; Electrocard | 2002 |
Tonin in rat heart with experimental hypertrophy.
Topics: Adrenergic beta-Agonists; Angiotensin II; Animals; Atrial Natriuretic Factor; Cardiomegaly; Disease | 2003 |
Beta-adrenergic activation initiates chamber dilatation in concentric hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Blood Pressure; Body Weight; Collagen; Dilatation, Pathologic; Di | 2003 |
Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression.
Topics: Adrenergic beta-Agonists; Animals; Aorta; Cattle; Caveolin 1; Caveolins; Cell Line; Diabetes Mellitu | 2004 |
Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Cardiomegaly; Celiprol | 2004 |
Furosemide and the progression of left ventricular dysfunction in experimental heart failure.
Topics: Adrenergic beta-Agonists; Aldosterone; Animals; Biomarkers; Disease Models, Animal; Disease Progress | 2004 |
Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function.
Topics: Adolescent; Cholangiopancreatography, Endoscopic Retrograde; Cholangiopancreatography, Magnetic Reso | 2007 |
Proteasome inhibition promotes regression of left ventricular hypertrophy.
Topics: Animals; Blotting, Western; Body Weight; Cardiotonic Agents; Cell Nucleus; Disease Progression; Echo | 2008 |
Decreased NO signaling leads to enhanced vasoconstrictor responsiveness in skeletal muscle arterioles of the ZDF rat prior to overt diabetes and hypertension.
Topics: Animals; Arterioles; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Disease Models, Anima | 2008 |
Response to isoproterenol as a prognostic indicator of evolution from hypertrophic cardiomyopathy to a phase resembling dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Disease Progression; Echocardiography; Female | 1995 |
Longitudinal clinical and electrophysiological assessment of patients with symptomatic Wolff-Parkinson-White syndrome and atrioventricular node reentrant tachycardia.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular N | 1996 |
Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression.
Topics: Adult; Aged; Cholera Toxin; Colforsin; Cyclic AMP; Disease Progression; Female; Humans; Isoprotereno | 1997 |
Effects of cardiac denervation on development of heart failure and catecholamine desensitization.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; Atropine Derivatives; Blood Pressure; | 1997 |
Influence of gender on control of arterial tone in experimental hypertension.
Topics: Acetylcholine; Adenosine Diphosphate; Adrenergic beta-Agonists; Animals; Apamin; Blood Pressure; Cal | 1998 |
Contribution of head-up tilt testing and ATP testing in assessing the mechanisms of vasovagal syndrome: preliminary results and potential therapeutic implications.
Topics: Adenosine Triphosphate; Age Factors; Aged; Bradycardia; Cardiac Pacing, Artificial; Cardiomyopathies | 1999 |
Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Topics: 1-Methyl-3-isobutylxanthine; Adenocarcinoma; Androgens; Biomarkers; Bombesin; Bucladesine; Calcium-C | 1999 |
Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene.
Topics: Adrenergic beta-Agonists; Animals; beta-Adrenergic Receptor Kinases; Cardiomegaly; Cardiomyopathy, D | 2001 |
Mechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart.
Topics: Adult; Aged; Binding, Competitive; Disease Progression; Down-Regulation; Female; Heart; Heart Failur | 2001 |